« Previous Next » Journal of the American Academy of Dermatology
Volume 60, Issue 2 , Pages 212-217 , February 2009

Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot study

Yasuo Kubota, MD
- Department of Dermatology, Faculty of Medicine, Kagawa University, Kagawa, Japan
- Reprint requests: Yasuo Kubota, MD, Department of Dermatology, Faculty of Medicine, Kagawa University, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan 761-0793.
Kozo Yoneda, MD
- Department of Dermatology, Faculty of Medicine, Kagawa University, Kagawa, Japan
Kozo Nakai, MD
- Department of Dermatology, Faculty of Medicine, Kagawa University, Kagawa, Japan
Junko Katsuura, MD
- Department of Dermatology, Faculty of Medicine, Kagawa University, Kagawa, Japan
Tetsuya Moriue, MD
- Department of Dermatology, Faculty of Medicine, Kagawa University, Kagawa, Japan
Yoshie Matsuoka, MD
- Department of Dermatology, Faculty of Medicine, Kagawa University, Kagawa, Japan
Izumi Miyamoto, MD
- Department of Dermatology, Faculty of Medicine, Kagawa University, Kagawa, Japan
Yukihiro Ohya, MD
- Division of Allergy, Department of Medical Specialties, National Center for Child Health and Development, Tokyo, Japan

,Accepted 23 September 2008.

Schematic presentation of topical sequential therapy and data-sampling periods using Eczema Area and Severity Index, pruritus and sleep disturbance scores, and quality-of-life (QOL) survey.

Schematic presentation of topical sequential therapy and data-sampling periods using Eczema Area and Severity Index, pruritus and sleep disturbance scores, and quality-of-life (QOL) survey.
- Full-Size Image
- Download to PowerPoint
Change from baseline to end of treatment (for up to 12 weeks) in Eczema Area and Severity Index (EASI) scores in pediatric patients with atopic dermatitis. Significant improvement was observed through

Change from baseline to end of treatment (for up to 12 weeks) in Eczema Area and Severity Index (EASI) scores in pediatric patients with atopic dermatitis. Significant improvement was observed throughout the course of sequential therapy (P < .001).
- Full-Size Image
- Download to PowerPoint
Change from baseline to end of treatment (12 weeks) in patients' assessment of pruritus (A) and sleep disturbance (B) in pediatric patients with atopic dermatitis. Significant improvement was observed

Change from baseline to end of treatment (12 weeks) in patients' assessment of pruritus (A) and sleep disturbance (B) in pediatric patients with atopic dermatitis. Significant improvement was observed throughout the course of sequential therapy (P < .001).
- Full-Size Image
- Download to PowerPoint
Clinical improvement of patient before (A) and after (B) 10 weeks of sequential therapy with tacrolimus ointment 0.03% and corticosteroid ointment (betamethasone valerate 0.12%).

Clinical improvement of patient before (A) and after (B) 10 weeks of sequential therapy with tacrolimus ointment 0.03% and corticosteroid ointment (betamethasone valerate 0.12%).
- Full-Size Image
- Download to PowerPoint
A, Children's Dermatology Life Quality Index (CDLQI). B, Infant's Dermatology Quality of Life (QOL) Index (IDQOL). QOL change scores from baseline to end of treatment (at maintenance phase). Significa

A, Children's Dermatology Life Quality Index (CDLQI). B, Infant's Dermatology Quality of Life (QOL) Index (IDQOL). QOL change scores from baseline to end of treatment (at maintenance phase). Significant improvement of QOL was observed throughout the course of sequential therapy (P < .05).
- Full-Size Image
- Download to PowerPoint
A, Children's Dermatology Life Quality Index (CDLQI). B, Infant's Dermatology Quality of Life Index (IDQOL). Topical sequential therapy significantly improved areas in which atopic dermatitis has grea

A, Children's Dermatology Life Quality Index (CDLQI). B, Infant's Dermatology Quality of Life Index (IDQOL). Topical sequential therapy significantly improved areas in which atopic dermatitis has greatest impact, including symptoms/feelings (CDLQI, IDQOL) and sleep disturbance (CDLQI).
- Full-Size Image
- Download to PowerPoint
Median difference between pretest (quality-of-life score before study) and retrospective pretest scores was significant at group level (P < .05), indicating that response shift bias was present. CDLQI

Median difference between pretest (quality-of-life score before study) and retrospective pretest scores was significant at group level (P < .05), indicating that response shift bias was present. CDLQI, Children's Dermatology Life Quality Index.
- Full-Size Image
- Download to PowerPoint